tradmap

XFOR X4 Pharmaceuticals, Inc

$4.20 +3.70%

Healthcare · Biological Products, (No Diagnostic Substances)

X4 Pharmaceuticals, Inc (XFOR) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $396 million. Shares last traded at $4.20, 13.0% below their 52-week high. Over the past year the stock is up 51.4%. Net profit margin is -225.6%, below the peer median of 6.3%. Revenue grew 1273.2% year over year.

Market Cap
$396M
Shares Out
94.3M
EPS (TTM)
$-6.58
P/E Ratio
P/S Ratio
11.28
P/B Ratio
2.35
Dividend / Share
Dividend Yield
52-Week High
$4.83
52-Week Low
$1.37
Volume
43,799
Avg Vol (3m)
33,150.73

Performance

1W
+7.97%
1M
+15.70%
3M
+0.84%
6M
+12.75%
YTD
+8.25%
1Y
+51.35%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
56.38
SMA (50)
$4.09
SMA (200)
$3.76
Price vs SMA50
+2.58%
Price vs SMA200
+11.58%
ATR (14)
$0.21

Financials

Revenue
$35M
Net Income
$-79M
Gross Margin
Operating Margin
-247.4%
Net Margin
-225.6%
Return on Equity
-47.0%
Return on Assets
-29.3%
Current Ratio
10.18
Debt / Equity
0.45
Revenue Growth (YoY)
+1273.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.16 2026-05-06
FY 2025 $-1.87 2026-03-17
Q3 2025 $-2.87 2025-11-05
Q2 2025 $-3.59 2025-08-08
Q1 2026 $0.04 2026-05-06
FY 2025 $-5.59 2026-03-17

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

XFOR vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
11.28 / 5.21 med
+116% premium
Net margin vs peers
-225.6% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.